Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia

Despite best evidence-based treatment including statins, residual cardiovascular risk poses a major challenge for clinicians in the twenty first century. Atherogenic dyslipidaemia, in particular elevated trigl...

Source: Cardiovascular Diabetology - October 4, 2017 Category: Cardiology Authors: Jean-Charles Fruchart Tags: Review Source Type: research